EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 7.0

ph-index = 6

Forward Citations = 159(Granted Patents)

Location History:

Emmendingen, DE (2006)
Denzlingen, DE (1997 - 2014)

Company Filing History:

Schering Aktiengesellschaft

patents

2 out of 5,444

University of Texas System

patents

4. 1 out of 6,850

Ciba-geigy Corporation

Gsf-international Research Institute for Environment and Health

where one patent can have more than one assignee

Years Active: 1997-2014

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8673930 - Pyrimidylaminobenzamide derivatives for systemic mastocytosis (2014-03-18),

2. 8268837 - Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia (2012-09-18),

3. 8119649 - Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia (2012-02-21),

4. 7666874 - Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome (2010-02-23),

5. 7122547 - Anthranilic acid amides and the use thereof as medicaments (2006-10-17),

6. 7002022 - N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF (2006-02-21),

7. 6878720 - VEGF receptor tyrosine kinase inhibitors (2005-04-12),

8. 5935976 - Antiviral ethers of aspartate protease substrate isosteres (1999-08-10),

9. 5807891 - Antiviral ethers of aspartate protease substrate isosteres (1998-09-15),

10. 5663200 - Antiviral ethers of aspartate protease substrate isosteres (1997-09-02),

Title: Jürgen Mestan: Innovator in Pharmaceutical Patents

Introduction

Jürgen Mestan is a notable inventor based in Denzlingen, Germany. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patents. With a total of 10 patents, Mestan has focused on developing treatments for various medical conditions.

Latest Patents

Mestan's latest patents include groundbreaking work on pyrimidylaminobenzamide derivatives. One of his inventions relates to the use of these derivatives for the preparation of a drug aimed at treating systemic mastocytosis. Another significant patent addresses the treatment of hypereosinophilic syndrome, specifically targeting FIP1L1-PDGFRα-induced or TEL-PDGFRβ-induced myeloproliferative diseases. This invention is particularly relevant for the curative and prophylactic treatment of hypereosinophilic syndrome, including cases resistant to imatinib.

Career Highlights

Throughout his career, Jürgen Mestan has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Novartis AG and Schering Aktiengesellschaft. His work in these organizations has allowed him to contribute to the development of innovative medical solutions.

Collaborations

Mestan has collaborated with several professionals in his field, including Paul William Manley and Andreas Huth. These collaborations have further enhanced his research and development efforts.

Conclusion

Jürgen Mestan's contributions to pharmaceutical innovations are noteworthy, particularly in the treatment of complex medical conditions. His patents reflect a commitment to advancing healthcare through scientific research and development.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

2 patents (EPO):

Please report any incorrect information to support@idiyas.com

1 patent pending (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.